为明确心肌病相关基因变异，研究人员对 40 例土耳其患者行临床外显子组测序（CES），发现MYBPC3变异最多。 心肌病是一种心肌细胞存在缺陷，进而导致心脏功能出现故障的病症。心肌病依据分子和（或）全身改变被分为三大类，且有多个亚型。该疾病的表现与 ...

Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data ...

With its first AAV gene therapy program, DiNA-001, in development for the treatment of MYBPC3 hypertrophic cardiomyopathy (HCM), the company and its platform is attracting significant partnering ...

Tenaya Therapeutics, Inc. announced the initiation of dosing in Cohort 2 of its MyPEAK™-1 Phase 1b/2 clinical trial for TN-201, aimed at treating MYBPC3-associated hypertrophic cardiomyopathy (HCM).

Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data Accepted for Late-Breaker ...

Business and Program Updates TN-201 - Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy In December 2024, Tenaya reported promising early data from the first cohort of patients in the ...

Pipeline and Near-term Catalysts: Tenaya's lead gene therapy candidates are TN-201, targeting MYBPC3-associated hypertrophic cardiomyopathy or HCM, and TN-401, targeting PKP2-associated ...